Cash ReservesPMV ended 2Q24 with $212.9M in cash, which should fund operations through 2025.
Clinical TrialsMeaningful response rates were seen in ovarian, breast, small-cell lung, and endometrial cancer types.
Financial PerformancePMV recorded a net loss of $0.02 per share—much narrower than previously estimated net loss of $0.31 per share.